RhumbLine Advisers
XFOR icon

RhumbLine Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

RhumbLine Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
+95,081
New +$390K ﹤0.01% 2847
2025
Q2 		– Sell
-6,281
Closed -$44.5K – 4273
2025
Q1 		$44.5K Buy
6,281
+323
+5% +$4.45K ﹤0.01% 3603
2024
Q4 		$131K Buy
5,958
+9
+0.2% +$143 ﹤0.01% 3391
2024
Q3 		$119K Sell
5,949
-293
-5% -$6.11K ﹤0.01% 3451
2024
Q2 		$109K Buy
6,242
+795
+15% +$26K ﹤0.01% 3499
2024
Q1 		$227K Buy
5,447
+101
+2% +$2.81K ﹤0.01% 3108
2023
Q4 		$135K Hold
5,346
– – ﹤0.01% 3352
2023
Q3 		$175K Buy
5,346
+215
+4% +$9.38K ﹤0.01% 3231
2023
Q2 		$299K Buy
+5,131
New +$264K ﹤0.01% 3021
2021
Q2 		– Sell
-688
Closed -$178K – 3118
2021
Q1 		$178K Sell
688
-25
-4% -$6.57K ﹤0.01% 2859
2020
Q4 		$138K Buy
713
+113
+19% +$22.2K ﹤0.01% 2918
2020
Q3 		$122K Sell
600
-52
-8% -$12.5K ﹤0.01% 2833
2020
Q2 		$182K Buy
+652
New +$179K ﹤0.01% 2806

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's XFOR Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 95,081 shares worth $444K. The stake represents ﹤0.01% of the portfolio and ranks #2847 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in XFOR as recently as Q1 2025.

RhumbLine Advisers first reported a position in XFOR in Q2 2020 and has held it in 13 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • RhumbLine Advisers held 95,081 shares of X4 Pharmaceuticals worth $444K as of Q2 2026.
  • X4 Pharmaceuticals was a new RhumbLine Advisers position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2847 holding.
  • RhumbLine Advisers first reported a position in X4 Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.